Bristol Myers Squibb and Bain Capital formed a joint venture.

Bristol Myers Squibb, a biopharmaceutical company, and Bain Capital, a private investment firm, formed a joint venture. Financial terms were not disclosed. “These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients. Bain Capital’s exceptional track record in building successful life science companies by providing focused development and dedicated resources makes them ideally suited to advance these assets to realize their full promise,” Julie Rozenblyum, BMS Senior Vice President.